RCS - Seed Innovations Ltd - Investee Company Update: Little Green Pharma

Seed InnovationsAnnouncement

01/05/2026 07:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260501:nRSA6826Ca&default-theme=true

RNS Number : 6826C  Seed Innovations Limited  01 May 2026

SEED Innovations Ltd / AIM: SEED / Sector: Closed End Investments

 

REACH Announcement

 

1 May 2026

SEED Innovations Limited

("SEED" or the "Company")

 

Investee Company Update: Little Green Pharma Ltd

 

SEED Innovations Ltd, the AIM-quoted investment company, is pleased to note
that its portfolio company, Little Green Pharma Ltd ("LGP"), has published its
Quarterly Activities Report and Appendix 4C for the period ending 31 March
2026 on the ASX.

 

SEED holds 7,324,796 ordinary shares in LGP, representing approximately 2.4%
of LGP's issued share capital.

 

The Quarterly Activities Report can be accessed via the following link:
https://investlittlegreenpharma.com/site/investor-centre/quarterly-reports1
(https://investlittlegreenpharma.com/site/investor-centre/quarterly-reports1)

 

- Ends -

 

For further information on the Company please visit: www.seedinnovations.co
(http://www.seedinnovations.co/)  or contact:

 

 Lance de Jersey    SEED Innovations Ltd             E: info@seedinnovations.co 

                                                      
 James Biddle       Beaumont Cornish Limited,        T: (0)20 7628 3396

 Roland Cornish     Nomad                             
 Isabella Pierre    Shard Capital Partners LLP       T: (0)20 7186 9927

 Damon Heath        Broker
 Ana Ribeiro        St Brides Partners Ltd,          E: seed@stbridespartners.co.uk

 Isabel de Salis    Financial PR

NOTES

SEED Innovations Ltd

SEED Innovations Ltd (SEED.L) is an AIM-quoted investing company focused on
providing access to high-growth robotics and AI ventures typically beyond the
reach of everyday investors. The Company also oversees a legacy portfolio in
wellness and life sciences, with a medium-term strategy to unlock its full
value.

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFSRSIIIVIR



            Copyright 2019 Regulatory News Service, all rights reserved